openPR Logo
Press release

Strategic Advancements in Drug Development are Beholding the Growth of OX40 Receptor Agonists Pipeline | Top Key Players are Pfizer, GSK, Kymab Ltd, AstraZeneca, Bristol-Myers Squibb, Incyte, Roche

06-14-2019 11:13 AM CET | Health & Medicine

Press release from: Pharma Proff

OX40 receptor holds a place in the tumor necrosis factor (TNF) superfamily whose interactions play an essential role in causing of different immune system ailments. OX40 interactions are amongst the most critical pathways that decide the extent of CD4 and CD8 T cell resistance. OX40 interactions also possess a crucial role in T cell immunity. OX40 is a co-stimulatory receptor that binds to OX40-Ligand (OX40L) to initiate a cascade, which is required for the activation of T cells. The OX40 receptor agonists have a similar impact as that of OX40L, and increases the OX40 signaling by subsequently reactivating the counter tumor resistant reaction in cancer patients. Currently, there is no approved drug that targets the OX40 receptor, therefore, drug manufacturers are constantly working in the direction to obtain new treatment strategies by targeting OX40 receptor.

Download the sample report at: https://www.pharmaproff.com/request-sample/1244

According to the research findings, majority of the pipeline drug candidates are being developed to be administered by intravenous route. It has been observed that the intravenous route of medication is convenient and provides improved patient’s compliance. Administration of OX40 receptor agonists through the intravenous route has shown promising results in clinical studies.

Get the detailed analysis at: https://www.pharmaproff.com/report/ox40-receptor-agonist-therapeutics-pipeline

Positive Clinical Results Play a Pivotal Role in OX40 Receptor Agonists Development

Companies that are involved in developing OX40 receptor agonists have shown positive clinical results in the various phases of drug development. For instance, in July 2018, Kymab Group Limited announced the positive data of phase I trial of KY1005 for the treatment of autoimmune diseases. The data demonstrated that KY1005 had a favorable safety profile and was well-tolerated. In addition, KY1005 was shown to block T-cell-driven inflammation in the skin of healthy volunteers. Kymab Group Limited has further planned to proceed with Phase II clinical trials for the treatment of atopic dermatitis, with additional plans to conduct parallel studies for graft-versus-host disease (GvHD).

Make enquiry before purchase at: https://www.pharmaproff.com/enquiry/1244

It has been observed that many pharmaceutical companies are entering into collaboration and licensing for the development of OX40 receptor agonists and their geographical expansion. For instance, in November 2011, AgonOx entered into an exclusive global partnership with MedImmune LLC to develop agonists using its OX40 platform. Under the terms of the agreement, MedImmune LLC will further conduct preclinical and clinical studies of OX-40 agonists (tumor-specific T-cell immunity stimulator) for the potential treatment of cancer.

Some of the players involved in the development of OX40 receptor agonists are Pfizer Inc., GlaxoSmithKline plc, Kymab Group Limited, MedImmune LLC, AstraZeneca PLC, Bristol-Myers Squibb Company, Incyte Corporation, Innovent Biologics (Suzhou) Co. Ltd., and F. Hoffmann-La Roche Ltd.

The report comprises detailed pipeline analysis of OX40 receptor agonists under development. Comprehensive insights on the pipeline products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the development of OX40 receptor agonists. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in this report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to OX40 receptor agonists.

Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com

About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Strategic Advancements in Drug Development are Beholding the Growth of OX40 Receptor Agonists Pipeline | Top Key Players are Pfizer, GSK, Kymab Ltd, AstraZeneca, Bristol-Myers Squibb, Incyte, Roche here

News-ID: 1775659 • Views:

More Releases from Pharma Proff

Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments
Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments
Interleukin-6 (IL-6) inhibitors currently exhibit a proliferating pipeline with 25+ therapeutic candidates. IL-6 is a cytokine encoded by IL-6 gene, which helps in the maturation of B cells and is actively involved in the inflammatory response. The IL-6 protein is primarily produced at the sites of acute and chronic inflammation, where it is secreted into the serum and brings a transcriptional inflammatory response through IL-6? receptor. This protein is assumed to
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developments
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developmen …
Retinitis pigmentosa therapeutics currently exhibits a proliferating pipeline with 25+ therapeutic candidates. Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete
Probiotics Therapeutics -Pipeline Analysis 2018, Clinical Trials & Results, Pate …
Probiotics are live microorganisms that produces beneficial effects in human gut. Probiotics can be taken as a dietary supplement. They prevent diarrhoea and help to reduce the symptoms of irritable bowel syndrome. Download the sample report at: https://www.pharmaproff.com/request-sample/1189 Probiotics comprise of a variety of microorganisms belonging to the Lactobacillus and Bifidobacterium groups. The only yeast probiotic that has proven to be effective is Saccharomyces boulardii. According to researchers, probiotics are effective in
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant Growth due to Increasing Strategic Developments in the Coming Years | Top Players are Orphazyme A/S, IntraBio Ltd., CTD Holdings, Inc., Mallinckrodt Pharmaceuticals, SOM Biotec
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant G …
Niemann-Pick disease is divided into four main types: type A, type B, type C1, and type C2. These types are classified on the basis of genetic cause and signs and symptoms of the disease. NPC is identified as a rare genetic disorder in which the body is unable to transport cholesterol and lipids inside the cells. This causes accumulation of these substances within various tissues of the body. These substances

All 5 Releases


More Releases for OX40

OX40 Antibody Market is estimated to reach USD 4.5 billion by 2034, expanding at …
" The global OX40 antibody market is valued at approximately $1.5 billion in 2024, driven by increasing investments in immunotherapy and advancements in cancer treatment modalities. The market is projected to grow significantly, reaching about $4.5 billion by 2034. This trajectory indicates a robust Compound Annual Growth Rate (CAGR) of 12.0% for the period of 2025 to 2034." Exactitude Consultancy., Ltd. released a research report titled "OX40 Antibody Market". This report
Ox40 Antibody Market Size, Share, Top Players, Developments, Growth Outlook 2024 …
This report segments the Ox40 Antibody Market comprehensively. The regional market sizes, concerning products by type, by application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments. Ox40 Antibody Market Size was estimated at 2.75 (USD Billion) in 2023. The Ox40
OX40 Ligand Inhibitors Market is Poised to boom by 2032, Assesses Delveinsight | …
(Albany, USA) The OX40 Ligand Inhibitors market size is anticipated to grow in the upcoming years, largely driven by heightened R&D endeavors across the 7MM. Furthermore, the competitive landscape remains relatively sparse, indicating that the regulatory approval process is likely to necessitate extensive clinical trials to establish both safety and efficacy. DelveInsight's OX40 Ligand Inhibitors Market Insights report offers a thorough understanding of prevailing treatment protocols, emerging therapies, individual therapy market
OX40 Ligand Inhibitors Market to Witness Significant Growth by 2032, Assesses De …
The OX40 Ligand Inhibitors market size is anticipated to grow in the upcoming years, largely driven by heightened R&D endeavors across the 7MM. Furthermore, the competitive landscape remains relatively sparse, indicating that the regulatory approval process is likely to necessitate extensive clinical trials to establish both safety and efficacy. DelveInsight's OX40 Ligand Inhibitors Market Insights report offers a thorough understanding of prevailing treatment protocols, emerging therapies, individual therapy market shares, and
OX40 Receptor Agonist Market Size/Share, Segmentation, Growth, Trends, Outlook, …
Global OX40 Receptor Agonist Market 2022-2028 - Global Industry Size, Supply Analysis, Price Analysis, Consumption and Production, Supplier and Cost Structure Analysis OX40 Receptor Agonist Market Overview The recent market intelligence study by the research analysts at Market Business Insights (MBI) takes a deep dive into inner operations of the global OX40 Receptor Agonist Market. It thoroughly examines the market landscape to give the readers an accurate insight into the current, as
OX40 Receptor Agonist Market Key Players, Type, Application, Drivers, Restraints …
The OX40 Receptor Agonist Market research report covers market production, definition, and application. It is essentially divided into a few key locales, import/ export, income, and developments in the OX40 Receptor Agonist Market. TheOX40 Receptor Agonist Market research report provides features of the vital market fragments and market players. In addition, it covers market patterns with market share, size, and development by region. It also examines critical participants based